Answer
Women of childbearing potential should use effective contraception with pregnancy rates below 1% throughout treatment with ofatumumab (Kesimpta) and for 6 months after the last dose.
Sources for this answer
- Kesimpta 20 mg solution for injection in pre-filled penNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 7Document updated
Sources checked